Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Progressive Corp (PGR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Progressive Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Progressive Corp trades at $232.41 (market cap $136.47B). The key difference: Progressive Corp is far larger — about 30.4× ACADIA Pharmaceuticals Inc.'s market cap, and Progressive Corp pays a 5.93% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PGR | |
|---|---|---|
Market Cap | $4.49B | $136.47B |
Sector | Health | Financials |
52-Week High | $28.06 | $252.68 |
52-Week Low | $20.06 | $190.40 |
Enterprise Value | $3.69B | $144.69B |
Dividend Yield | — | 5.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Progressive (PGR) trades at $234.40, up 0.94% with a bullish technical signal and strong fundamentals. Recent earnings beat expectations with Q1 2026 EPS of $4.96 versus $4.85 estimate, continuing a trend of operational strength. Revenue grew to $87.64B in 2025 with net income margin at 12.93%, while analyst consensus price target is $235.67. The stock shows resilience with positive media coverage highlighting earnings growth and leadership changes.
Outlook remains positive driven by earnings momentum and scale advantages in auto insurance. Key risks include competitive pressures and macroeconomic sensitivity. Institutional sentiment is mixed with 41.46% buy ratings, but the stock's valuation at P/E 11.78 offers room for upside if earnings trends persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
